HIIFS
SCNI

Harel Insurance Investments & Financial Services’s Scinai Immunotherapeutics SCNI Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-105
Closed -$57K – 496
2018
Q1 		$57K Buy
+105
New +$65.5K ﹤0.01% 299

Other funds holding SCNI

II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
BHB
Bank Hapoalim BM Tel Aviv, Israel $1.5B AUM 26.39% 1-Year Est. Return
VIA
Vantage Investment Advisors State College, Pennsylvania $477M AUM 17.38% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 27.61% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Harel Insurance Investments & Financial Services's SCNI Position: Q2 2018 in Review

Harel Insurance Investments & Financial Services sold out of Scinai Immunotherapeutics (SCNI) in Q2 2018, closing a stake of 105 shares — an estimated $57K sold.

Harel Insurance Investments & Financial Services first reported a position in SCNI in Q1 2018 and held it in 1 quarter. The position peaked at $57K in Q1 2018. 12 funds tracked by Wall St. Rank hold SCNI as of Q2 2018.

  • Harel Insurance Investments & Financial Services reported no remaining Scinai Immunotherapeutics position as of Q2 2018 after selling out during the quarter.
  • Harel Insurance Investments & Financial Services sold 105 Scinai Immunotherapeutics shares in Q2 2018, an estimated $57K.
  • Harel Insurance Investments & Financial Services first reported a position in Scinai Immunotherapeutics in Q1 2018 and held it in 1 quarter.
  • Harel Insurance Investments & Financial Services's Scinai Immunotherapeutics position peaked at $57K in Q1 2018.
  • 12 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2018.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q2 2018, filed 30 Jul 2018.